Sign in

    Martine Rothblatt

    Chairperson and CEO at United Therapeutics Corp
    Board
    Since 1996
    Age
    70 years
    Education
    Earned a Ph.D. in medical ethics from the University of London, a J.D., and an M.B.A.
    Tenure
    Founded the company in 1996 and has served as Chairperson and Chief Executive Officer since inception.

    Also at United Therapeutics Corp

    JCE
    James C. Edgemond
    CFO and Treasurer
    MB
    Michael Benkowitz
    President and COO
    PAM
    Paul A. Mahon
    EVP, General Counsel, and Corporate Secretary

    About

    Martine Rothblatt is a pioneering entrepreneur with a unique blend of expertise in biotechnology, satellite communications, and ethics.

    She founded the company in 1996 and has driven its mission to develop innovative therapies for rare diseases, serving as Chairperson and Chief Executive Officer since its inception.

    Her professional journey includes groundbreaking work in xenotransplantation and global virus bio-surveillance, reflecting her commitment to transforming healthcare through innovation.

    Before her foray into biotechnology, she was instrumental in establishing the satellite radio industry, laying the foundations for services like SiriusXM, and continues to contribute as an inventor with several U.S. patents, further highlighting her multifaceted career.

    $UTHR Performance Under Martine Rothblatt

    Past Roles

    OrganizationRoleDate RangeDetails
    SiriusXMFounderPre-1996Created the satellite radio company before founding UTHR.

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary $1,500,000Effective March 5, 2023Reflects a 6.0% increase over 2022 base salary.
    Supplemental Executive Retirement Plan (SERP) $14,175,604Potential payment upon termination or change in control as of December 31, 2023Represents the accrued value under the SERP.
    Health and Other Benefits $148,894As stipulated in the employment agreementIncludes automobile leasing, maintenance, and insurance costs.

    Performance Compensation

    Data from  FY 2023

    Non-Equity Incentive Plan Compensation

    MetricValueNotes
    Base Salary$1,500,000 Used in cash incentive calculation
    Cash Incentive Award Target %125%
    Milestone Attainment100% Achievement of pre-established performance metrics
    Financial Multiplier146% Based on financial performance
    Patient Multiplier152% Based on patient-related metrics
    Threshold$703,125
    Target$1,875,000
    Maximum$5,625,000
    Earned Bonus$4,161,000 Calculated as: Base Salary × 125% × 100% × 146% × 152%
    Payment SchedulePaid in March 2024 Cash incentive based on 2023 performance

    Stock Options (Equity Incentive Plan Awards)

    MetricValueNotes
    Performance Period2023–2025 Three-year performance period
    Grant DateMarch 15, 2023
    Grant Date Fair Value$5,926,252 Target value of the stock options
    Grant Date Stock Price$85.59 Exercise or base price
    Target Number of Shares69,240
    Maximum Number of Shares207,720 Maximum potential award value of $17,778,755
    Vesting ScheduleCliff vest at end of period Contingent upon meeting performance criteria (average cash profits margin not disclosed)

    Restricted Stock Units (RSUs) (Equity Incentive Plan Awards)

    MetricValueNotes
    Performance Period2023–2025 Three-year performance period
    Grant DateMarch 15, 2023
    Grant Date Stock Price$217.50
    RSUs - Revenue Growth (Weight 25%)12,360 target / 37,080 maximum Target fair value: $5,376,600
    RSUs - R&D Milestones (Weight 25%)12,360 target / 37,080 maximum Target fair value: $5,376,600
    Total RSUs24,720 target / 74,160 maximum Total target grant date fair value: $10,753,200
    Vesting ScheduleCliff vest at end of period Based on achievement of performance conditions